MétaCan
Menu
Back to cohort
Record W7131757302

HLA-A03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis

2025· article· W7131757302 on OpenAlexfundno aff
B. L. Zhang, T. Schneider-Hohendorf, R. Elyanow, B. Pignolet, S. Falk, C. Wunsch, M. Deffner, E. Yusko, D. May, D. Mattox, E. Dawin, L. Gerdes, F. Bucciarelli, L. Revie, G. Antony, S. Jarius, C. Seidel, M. Senel, S. Bittner, F. Luessi, J. Havla, M. Knop, M. Friese, S. Rothacher, A. Salmen, F. Hayashi, R. Henry, S. Caillier, A. Santaniello, M. Seipelt, C. Heesen, S. Nischwitz, A. Bayas, H. Tumani, F. Then Bergh, G. Meyer Zu Horste, T. Kumpfel, C. Gross, B. Wildemann, M. Kerschensteiner, R. Gold, S. Meuth, F. Zipp, B. Cree, J. Oksenberg, M. Wilson, S. Hauser, S. Zamvil, L. Klotz, R. Liblau, H. Robins, J. Sabatino, H. Wiendl, N. Schwab

Bibliographic record

VenueMPG.PuRe (Max Planck Society) · 2025
Typearticle
Language
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsnot available
FundersNovo NordiskHeinrich-Heine-Universität DüsseldorfSanofi GenzymeEMD SeronoNational Institutes of HealthBundesministerium für Bildung und ForschungValhalla FoundationDeutsche ForschungsgemeinschaftDeutschen Multiple Sklerose GesellschaftBayer VitalDeutscher Akademischer AustauschdienstMultiple Sclerosis SocietyBiogenModernaBundesinstitut für RisikobewertungChugai PharmaceuticalGuthy-Jackson Charitable FoundationUniversity of California, San FranciscoAlzheimer SocietyNGM BiopharmaceuticalsAdaptive BiotechnologiesFresenius Medical Care North AmericaH. Lundbeck A/SBaxaltaSanofiTG TherapeuticsGenentechGemeinsame BundesausschussJapan Society for the Promotion of ScienceDeutsche Alzheimer GesellschaftMax-Planck-GesellschaftAmicus TherapeuticsUniversity of BernArgenxDaimler und Benz StiftungNovartisCelgeneGrifolsF. Hoffmann-La RocheAlexion PharmaceuticalsGilead SciencesNeuraxpharmBristol-Myers SquibbTeva Pharmaceutical IndustriesCSL BehringEli Lilly and CompanySamsungNovo Nordisk PharmaAmgen
KeywordsGlatiramer acetateCohortMultiple sclerosisRetrospective cohort studyBiomarkerHuman leukocyte antigenBiosimilarPharmacogenetics
DOInot available

Abstract

fetched live from OpenAlex

BACKGROUND: Glatiramer acetate (GA) is a well-tolerated treatment for multiple sclerosis (MS) and comparable in its efficacy to high-dose interferon beta (IFN). As a lack of validated treatment response biomarkers for MS hampers progress in personalised treatment, the study goal was to search for biomarkers of a successful treatment response utilising the known observation of T-cell expansions after GA treatment. METHODS: T-cell receptor beta chain (TRB) sequencing was performed in 3021 patients with MS: a discovery cohort of 1627 patients with MS, 204 of whom had previously been treated with GA, and then validated in 1394 patients with MS, 424 of whom had previously been treated with GA. Clinical data from 1987 patients with MS treated with GA or IFN and available HLA information from the NationMS, ACP, EPIC, BIONAT, and CombiRx trial cohorts were used for a subsequent analysis. FINDINGS: Common GA-associated TRB expansions were exclusively detected in HLA-A03:01 or in HLA-DRB115:01 backgrounds, within CD8+ effector- or CD4+ central-memory T cells. Both sets of common sequences clonally expanded after GA treatment in a first validation cohort and predicted GA exposure in two further validation cohorts. To evaluate whether restriction of public TRBs to only two HLA alleles is also associated with GA's clinical efficacy, we analysed five cohorts of patients with MS for a potential benefit of the two HLAs concerning the GA response compared to IFN. We consistently found positive interactions with HLA-A03:01. This included a relative reduction in relapse risk compared to IFN in HLA-A03:01 carriers of 33% (CombiRx: GA + IFN arm: HR 0.67 [95% CI: 0.47-0.96], p = 0.0269) and 34% (CombiRx: GA arm: HR 0.66 [95% CI: 0.45-0.98], p = 0.0377), and in risk to first relapse of 63% (NationMS: HR 0.37 [95% CI: 0.16-0.88], p = 0.0246), but no positive association with DRB115:01. INTERPRETATION: HLA-A03:01 carrying patients with MS specifically benefit from GA treatment and GA significantly outperforms IFN in these patients. Therefore, determining HLA-A03:01 status before choosing a platform treatment for MS, would allow for a personalised treatment decision between GA and IFN. FUNDING: German Research Foundation, National Institutes of Health, National Multiple Sclerosis Society, Valhalla Foundation, Westridge Foundation, Mayer Foundation, German Federal Ministry of Education and Research.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.052
GPT teacher head0.324
Teacher spread0.271 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueMPG.PuRe (Max Planck Society)Same topicMultiple Sclerosis Research StudiesFrench-language works237,207